The extended-release delivery coupled with the 351mg dose allows for single-dose initiation. Erzofri ® (paliperidone palmitate) extended-release injectable suspension is now available for the the ...
PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI ® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in ...
Erzofri is an atypical antipsychotic that is administered once a month as an intramuscular injection. The Food and Drug Administration (FDA) has approved Erzofri ® (paliperidone palmitate) ...
Luye Pharma Group, an international pharmaceutical company, announced that Erzofri (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in the US for ...
Erzofri is the first patented paliperidone palmitate long-acting injectable developed in China to receive FDA approval for treating schizophrenia and schizoaffective disorder, company says. The FDA ...
(MENAFN- PR Newswire) PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results